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Summary
Patients with primary biliary cirrhosis (PBC) frequently have autoantibodies against a 210-kD
integral glycoprotein of the nuclear envelope pore membrane. This protein, termed gp210, has
a 1,783-amino acid amino-terminal domain located in the perinuclear space, a 20-amino acid
transmembrane segment, and a 58-amino acid cytoplasmic carboxy-terminal tail. We now
demonstrate that autoantibodies from 25 patients with PBC that recognize gp210 react with
the cytoplasmic carboxy-terminal tail while none react with unmodified linear epitopes in the
amino-terminal domain. The epitope(s)recognized by autoantibodies from all 25 patients is contained
within a stretch of 15 amino acids. The recognized amino acid sequence is homologous to the
protein products of the Escherichia coli mutY gene and Salmonella typhimurium mutB gene with
an exact identity of six consecutive amino acids, suggesting that anti-gp210 antibodies may arise
by molecular mimicry of bacterial antigenic determinants.
P
atients with liver and autoimmunediseases frequently have
autoantibodies that recognize proteins of the nuclear enve-
lope (1). The nuclear envelope is composed of the nuclear
lamina, the nuclear pore complexes, and the nuclear mem-
branes (for reviews see references 1-3). The lamina is a mesh-
work of intermediate filament proteins termed lamins and
the pore complexes are composed ofmore than 100 different
polypeptides. Three morphologically distinct but intercon-
nected membranes are found in the nuclear envelope: the inner
nuclear membrane, the outer nuclear membrane, and the nu-
clearpore membrane. The inner and outer nuclear membranes
are separated from each other by the perinuclear space which
is continuous with the lumen of the endoplasmic reticulum
(ER). These two membranes are connected at numerous points
by the nuclear pore membranes that also serve as the attach-
ment sites for the pore complexes. Although the three nu-
clear envelope membranes are continuous, integral proteins
are not randomly distributed between them and unique pro-
teins reside in each of these membranes.
About one third ofpatients with primary biliary cirrhosis
(PBC) have serum antibodies that recognize the protein com-
ponents of the nuclear lamina or the nuclear membranes. Oc-
casionally, patients with PBC have antibodies that recognize
the nuclear lamins (4), although these autoantibodies are more
commonly detected in patients with autoimmune hepatitis
(5, 6) or systemic lupus erythematosus (7). Few patients with
PBC have autoantibodies against the lamin B receptor (8),
a polytopic protein of the inner nuclear membrane (9, 10).
As many as 25% ofpatients with PBC, and apparently none
thus far described with other diseases, have serum antibodies
that recognize a 200-kD protein of the nuclear envelope (4,
11-13) that has been identified as gp210 (14), an integral gly-
coprotein of the nuclear pore membrane (15). Gp210 is com-
posedofan amino-terminal domain of 1,783 amino acids (after
cleavage of the amino-terminal signal sequence) that is lo-
cated in the perinuclear space, a 20-amino acid transmem-
brane segment that spans the nuclear pore membrane, and
a cytoplasmic carboxy-terminal tail domain of58 amino acids
(16, 17). Residues in the amino-terminal domain are glyco-
sylated (16). The transmembrane segment and cytoplasmic
tail ofgp210 both contain signals for targeting to the nuclear
pore membrane (18) and the cytoplasmic tail may interact
with proteins of the nuclear pore complex (16).
It is not known why patients with PBC develop autoanti-
bodies against gp210 or whether these antibodies recognize
a specific domain ofthis integral membrane protein. It is also
unclear as to how this intracellular protein, or the autoanti-
bodies that recognize it, are related to the pathogenesis of
PBC. Identification of the epitope(s) of gp210 recognizedby
autoantibodies would provide information to help answer these
questions. Identification of the recognized epitope(s) would
also facilitate the development of simple assays to detect gp210
autoantibodies, such as those utilizing polypeptide antigens
that have been clinically useful for detecting antimitochon-
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gion of gp210 that contains the epitope(s) recognized by au-
toantibodies from patients with PBC.
Materials and Methods
Autoantibodies. 15 serum samples with antibodies shown to
recognize a full-length gp210 fusion protein were obtained from
a series of 159 patients with PBC followed at The Mount Sinai
Medical Center in New York City (13) . 10 serum samples con-
taining antibodies that recognize purified gp210 (14) were provided
by Dr.J.-C . Courvalin (Institut Jacques Monod, University Paris
7, Paris, France) and obtained from a previously published series
of 150 patients with PBC (4).
Plasmid Construction andFusion Protein Expression.
￿
ThepGEX-
2T vector (Pharmacia LKB, Piscataway, NJ) was used to make
plasmid constructs that express various regions of rat gp210 as
glutathione-S-transferree (GST) fusion proteins (21) . To generate
cDNAs coding for the various regions of gp210, 25 cycles ofPCR
were performed as described (22) using the GeneAmp Kit (The
Perkin ElmerCorp., Norwalk, CT) andthe following parameters :
denaturation at 94°Cfor1min, annealing at 50°C for 2min, and
extension at 72°C for 3 min. A full-length gp210 cDNA (18)
provided by Dr. R .WWozniak (Laboratory ofCell Biology, The
Rockefeller University, NewYork)was used as the template . Based
on the previously published sequence of gp210 (16), PCRprimers
were designed to amplify portions ofcDNA coding for the regions
of the protein shown in Figs . 1 and 2 . Restriction sites were en-
gineered into the 5' ends of the PCRprimers to facilitate cloning
of the amplified products into the BamHI and/or EcoRl sites of
pGEX-2T . Amplified products were purified from PCRreactions
mixtures using either the GeneClean II Kit (Bio 101, Inc., Vista,
CA) or phenol/chloroform extraction (23) . The purifiedDNAwas
digested with the appropriate restriction enzymes, purified again,
and ligated into pGEX-2T that was also digested with the appro-
priate restriction enzymes. Escherichia coli strains BB-4 or JM101
(Stratagene, LaJolla, CA) were transformed by standard methods
(23) and the recombinant plasmids were analyzed by restriction
digestion . All plasmids encoding gp210 carboxy-terminal domain
fusion proteins were also analyzed by dideoxy chain termination
sequencing (24) using theSequenase Version II Kit (United States
Biochemical, Cleveland, OH) . GST fusion proteins were expressed
as described (21) . Fusion proteins were purified on glutathione-
Sepharose (Pharmacia LKB) as described (21), except forfusion pro-
teins 2, 3, 4, and 5 (Fig. 1) forwhich whole bacterial cell lysates
were used in immunoblotting experiments, as the proteins were
hydrophobic and difficult to solubilize. Expression of the fusion
proteins was confirmed by immunoblotting with antibodies that




under reducing conditions according to Laemmh (25). Proteins were
transferred to nitrocellulose (Schleicher and Schuell, Keene, NH)
using a semi-dry blotting apparatus (Bio-Rad Laboratories, Rich-
mond, CA) . Immunoblotting with human serum, diluted from
1:100 to 1:1,000, was performed as previously described (8) using
1211-labeled protein A (DuPont-NEN, Boston, MA) to detect the
primary antibody. To obtain autoradiograms, immunoblots were
exposed toXARfilm (Eastman KodakCo., Rochester, NY orJersey
Lab andGlove Supply, Livingston, NJ) at -80°Cwith intensifying
screens for 14-48 h.
Sequence Analysis.
￿
Protein homology searches were performed
using the computer facilities of theAdvanced Scientific Computing
Laboratory, National Cancer InstituteSupercomputer Center (Fred-
erick, MD)and version 7.13 of theGCG sequence analysis software
package (Genetics Computer Group, Inc., Madison, WI) (26) .
Chemical Reagents.
￿
Routine chemical reagents were obtained
from either Sigma ChemicalCompany (St . Louis, MO) or Fisher
Scientific Co . (Pittsburgh, PA) . Restriction enzymesandDNA li-
gase were from New England Biolabs (Beverly, MA) .
Results
Immunoblotting of GST fusion proteins (Fig. 1 a) was
performed to determine which domains of gp210 were rec-
ognizedby antibodies in 25 serum samples from patients with
PBC. Antibodies from all 25 patients recognized a fusion
protein (Fig. 1, no. 6) that containedthe 58 amino acids com-
prising the carboxy-terminal tail domain of gp210 . None of
the patients had autoantibodies that recognized the amino-
terminal domain of gp210 (Fig . 1, nos. 1-5) . The serum
Figure 1 .
￿
Autoantibodies from patients with
PBC recognize the 58-amino acid cytoplasmic tail
ofnuclear pore membrane glycoprotein gp210. (a)
Diagram of nuclear pore glycoprotein gp210 and
regions expressed as GST fusion proteins. The
cleaved amino-terminal signal sequence (SS) and
single transmembrane domain (TM) are indicated,
as are the regions that are located in the perinuclear
space and that face the nuclear pore . Regions la-
beled 1 through 6 were expressed as GSTfusion
proteins. Thenumber of patients out of 25 with
antibodies that recognized therespective fusion pro-
teins is given in parentheses . Fusion proteins 1-6
contained the regions ofgp210 between the amino
acidsindicated according to the numbering ofWoz-
niak et al . (reference 16): Fusion protein 1, 26-222 ;
fusion protein 2, 205-574; fusion protein 3, 561-
1113; fusion protein 4, 1101-1481; fusion protein
5, 1461-1808; fusion protein 6, 1829-1886 . The
hydrophobiccleaved amino terminal signal sequence
and transmembrane domain were not included in any of the fusion proteins. (b) Autoradiogram of a representative immunoblot showing autoantibody
reactivity with fusion protein 6 and lack of reactivity with fusion proteins 1-5. This pattern was seen with serum samples from all 25 patients.
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membrane segment, which is integrated in the lipid bilayer,
or the signal sequence, which is cleaved from mature gp210 .
To identify a smaller epitope(s) within the carboxy-terminal
tail domain of gp210, additional overlapping fusion proteins
were expressed (Fig. 2 a) . Antibodies from all 25 patients
recognized fusion protein 11 (Fig. 2) but did not recognize
fusion protein 7 (Fig. 2), demonstrating that the epitope(s)
is contained within the last 34 amino acids of gp210. All
of the samples contained antibodies that also recognized fu-
sion protein 12 (Fig. 2), showing that the epitope(s) was con-
tained within the last 18 amino acids of the carboxy-terminal
domain . Onlytwo samples contained antibodies that reacted
with fusion protein 8 (immunoblots not shown) that over-
lapped with the amino-terminal side offusion protein 12 (Fig.
2 a) . From immunoblotting of fusion proteins 8, 9, 10, and
12, the epitope(s) recognized by all of the autoantibodies was
shown to be present within a 15-amino acid stretch of se-
quence asp-arg-lys-ala-ser-pro-pro-ser-gly-leu-trp-ser-pro-ala-
tyr. The first 9 amino acids of this sequence were sufficient
for recognition by antibodies from 2 of 25 patients and the
first 13 were sufficient for recognition by 23 samples. Although
the fusion proteins contained portions of rat gp210, major
Figure 2 .
￿
Autoantibodies from patients withPBC recognize a stretch
of 15 amino acids in the cytoplasmic tail of gp210 that is homologous
to a sequence present in an E. coli protein . (a) Amino acid sequence of
the cytoplasmic tail of gp210 and the regions labeled 7 through 12 that
were expressed asGSTfusion proteins are shown . The number of patients
out of 25 with antibodies that recognized the fusion proteins containing
regions 7-12 is given in parentheses. The underlined amino acids are the
smallest stretch recognized by all 25 antibodies. Shown at the top right
is a stretch of amino acids found in the protein product oftheE. coli mutY
gene and its homology with the region of gp210 recognized by the au-
toantibodies . Abbreviations for amino acids are : H, histidine ; T, threo-
nine ; V, valine; C, cysteine ; A, alanine ; P, proline ; R, arginine; E, glu-
tamic acid; L, leucine ; S, serine;Q glutamine ; Y, tyrosine, F, phenylalanine;
N, asparagine ; D, aspartic acid; K, lysine ; G, glycine ; W, tryptophan . (b)
Autoradiogram of a representative immunoblot with one patient's serum
showing autoantibody reactivity with fusion proteins 9, 10, 11, and 12
and lack of reactivity with fusion proteins 7 and 8 . This pattern was ob-
served for 21 ofthe 25 patients . Antibodies from two patients additionally
recognized fusion protein 8 . Antibodies from two others recognized fu-
sion proteins 10, 11, and 12 but not fusion protein 9.
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sequence differences in this region between rats andhumans
were unlikely as the autoantibodies reacted with nuclear pores
when human cells were examined by immunofluorescence
microscopy (data not shown) .
Search of the translatedGenBank showed that the 15-amino
acid sequence recognized by all ofthe autoantibodies was ho-
mologous to a portion of the protein products of the E . coli
muff gene (Fig. 2) and the Salmonella typhimurium mutB gene
(46.7% identity between each of them and the gp210 se-
quence) . A stretch of six consecutive amino acids was iden-
tical in these three proteins (Fig . 2) . Several other proteins
were found that had sequence identities of 46.7% over a 15-
amino acid stretch and two of these, the product of thehuman
c-myc oncogene and human pro-galanin, had six different con-
secutive identical amino acids. One protein, carp urotensin
II-a, had the same six consecutive amino acids common to
gp210 and the bacterial polypeptides but only 40% overall
identity over the 15-amino acid stretch .
Discussion
PBC is characterized by nonsuppurative inflammatory de-
struction of intrahepatic bile ducts that leads to cirrhosis (27,
28) . Autoantibodies against the E2 subunits of mitochon-
drial pyruvate dehydrogenase and related enzyme complexes
are found in about 90% of patients (19, 20, 29-32) . Anti-
bodies to nuclear proteins including histones (33), Sp-100 (34),
nuclear lamins (4), the laminB receptor (8), gp210 (4, 11-14),
and others are also commonly found . Because of the pres-
ence of autoantibodies in almost all cases, PBC has been called
a paradigmatic autoimmune disease (35) . However, a paradox
presented byPBC is how proteins that are present in all cells,
and the autoantibodies that recognize them, relate to the patho-
logical process of bile duct destruction (35) .
Analysis of the epitopes of the intracellular protein antigens
inPBC could provide insight intohow specific autoantibodies
arise and how autoimmunity underlies pathogenesis. In the
present study, we have shown that autoantibodies from pa-
tients with PBC recognize a restricted region within the
carboxy-terminal domain of nuclear pore membrane glyco-
protein gp210 . Previous work has demonstrated that this do-
main is located in the cytoplasm and faces the nuclear pore
complex (16, 17) . Although the fusion proteins used in this
study may not display nonlinear or posttranslationally modified
epitopes in the noncytoplasmic domain of gp210 with which
autoantibodies may react in vivo, all of the serum samples
examined nonetheless contained autoantibodies that recog-
nized a restricted linear region of only 15 amino acids in the
cytoplasmic tail. This differs from that seen with autoanti-
bodies against lamin B, another nuclear envelope protein,
where autoantibodies from 10 different patients with systemic
lupus erythematosus reacted with at least five distinct linear
epitopes along the length of the molecule (36) .
Some investigators (37, 38) have proposed that molecular
mimicry ofbacterial antigens is responsible for antibody gener-
ation and pathogenesis in PBC . In molecular mimicry, an
immune response is induced by a specific antigenic determinant
ofan infecting agent and this response is subsequently directedagainst an epitope on a host polypeptide leading to autoim-
munity and possibly disease (38, 39). Molecular mimicry of
a peptide sequence in myelin basicprotein by a viral polypep-
tide determinant can cause an immune response leading to
nervous system injury (40). Other examples of sequence
similarities between microbial and host proteins in which dis-
ease may be caused by molecular mimicry include similari-
ties between the sequences of adenovirus-12 ElB protein and
A-gliadin (41) and Klebsiellapneumonia nitrogenase and HLA-
B27 (42). Molecular mimicry, in the former case, may un-
derlie the pathogenesis ofceliac disease and, in the latercase,
ankylosing spondylitis and Reiter's syndrome.
Molecular mimicry has been postulated to be responsible
for the generation of antimitochondrial antibodies in PBC
because the autoepitope(s) of the E2 subunits of the mam-
malian mitochondrial enzymes (19, 20, 31) are homologous
to the E2 subunits ofthe E. coli pyruvate dehydrogenase com-
plex. Along these lines, patients with PBC have an increased
incidence of E. coli urinary tract infections (43, 44) . It has
also been shown that HLA-DR-oi, which is abnormally ex-
pressed on the surface of bile duct epithelial cells in PBC (45),
shares homology with the E2 epitope(s), possibly relating
the autoantibodies to the pathological injury (37, 38) . Like
the epitopes of the mitochondrial antigens recognizedby au-
toantibodies from patients with PBC, the region of gp210
recognizedby autoantibodies also shares sequence homology
with an E. coli protein, the adenine glycosylase encoded by
the mutY gene (46, 47). The homologous sequence is also
present in the product of the similar S. typhimurium mutB
gene (48). Although the identification of sequence similarity
between the gp210 autoepitope(s) and bacterial gene prod-
ucts may be fortuitous, these results provide additional evi-
dence that supports the hypothesis that molecular mimicry
is responsible for the generation of autoantibodies in patients
with PBC. Homologous bile duct cell surface antigens could
hypothetically link this immune response to the patholog-
References
ical process in PBC, but candidate proteins have not yet been
identified.
Another possibility that could result in the generation of
autoantibodies against gp210 in patients with PBC is that
polypeptides derived from the protein's cytoplasmic tail are
abnormally expressed on the plasma membranes of certain
cells. It is possible that the cytoplasmic tail ofgp210 is degraded
into peptides that are transported to the cell surface and then
recognized as non-self. One example of the cell surface ex-
pression of peptides that arise from the degradation of pro-
teins located in the nucleus or cytoplasm are those presented
by MHC class I (49). These proteolytic peptides are trans-
ported into the ER lumen (49), and once in the ER lumen,
the peptides, which are from 9 to 11 amino acids, bind to
MHC class I proteins and are ultimately expressed on the
plasma membrane (49). Although speculative, it is possible
that a similar mechanism could be responsible for abnormal
cell surface expression ofgp210 peptides. If this were the case,
our data would suggest that regions of a transmembrane pro-
tein residing in the ER lumen (perinuclear space) are pro-
tected from the proteolysis that generates such peptides.
In summary, autoantibodies against nuclear pore membrane
glycoprotein gp210 in patients with PBC recognize a restricted
region in the cytoplasmic tail. The autoepitope(s) is contained
within a 15-amino acid stretch homologous to a portion of
the E. coli mutY gene product, suggesting that gp210 au-
toantibodies could arise by molecular mimicry of a bacterial
antigenic determinant. Alternatively, such antibodies may be
generated because of abnormal expression of this epitope(s)
on the cell surface in patients with PBC. Regardless of their
mechanism of generation, anti-gp210 antibodies can be de-
tected using small polypeptides. This will permit the devel-
opment of clinically useful assays to detect gp210 autoanti-
bodies that are highly specific for a diagnosis of PBC and
present in up to 25% of these patients.
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